Kodawire — SEE EVERY SIDE. KNOW THE TRUTH.Kodawire — SEE EVERY SIDE. KNOW THE TRUTH.
Top storiesTrendingBlindspotLocalTopics
Sign in
WorldPoliticsBusinessTechHealthScienceClimateEducationSportsCultureAfricaEuropeAsia-PacificAmericasMiddle East
Kodawire — SEE EVERY SIDE. KNOW THE TRUTH.Kodawire — SEE EVERY SIDE. KNOW THE TRUTH.

Kodawire puts left, center and right coverage of the same story side by side, with links to every original report, so you can see what each outlet emphasises — and what it leaves out.

Sections

  • World
  • Politics
  • Business
  • Technology
  • Health
  • Science
  • Climate

Regions

  • Africa
  • Europe
  • Asia-Pacific
  • Americas
  • Middle East

Read

  • Top stories
  • Trending today
  • Blindspot
  • Local news
  • All topics

Kodawire

  • About us
  • How we rate bias
  • Trust & ratings
  • Contact

© 2026 Kodawire. Headlines and excerpts belong to their publishers.

PrivacyTerms & DMCA
/
/
Back

Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE)

3 sources

Investing.com21h ago

Centerprovisional

Arcus Biosciences prices $250 million stock offering at $17.50

Arcus Biosciences slides 20% on stock offering, kidney-cancer…

Original

Seeking Alpha (US)25h ago

Centerprovisional

Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE)

Arcus Biosciences slides 20% on stock offering, kidney-cancer…

Original

Seeking Alpha (US)25h ago

Centerprovisional

Arcus Biosciences slides 20% on stock offering, kidney-cancer data

Arcus Biosciences slides 20% on stock offering, kidney-cancer…

Original

Spectrum

L 0%C 100%R 0%